Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.23% to $8.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.22% to $8.78 Tuesday, on what proved to be an all-around mixed ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...